Professor Gill's team will be presenting 4 research papers in "The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) 17-20 February 2011, QSNCC, Bangkok Thailand" Professor Gill's team will be presenting 4 research papers in "The 21st Conference of the Asian Pacific Association for the Study of the Liver […]

Professor Gill\'S team will be presenting research work at EASL (european association of study of liver diseases) annual conference being held in Berlin Germany in April 2011 Our Reference: EASL2011_PO_ 305 Dear Muzaffar Gill, On behalf of the Scientific Programme Committee, we are very pleased to inform you that your abstract A-343-0024-00305 entitled: "VIROLOGICAL RELAPSE RATE […]

Professor Gill's team work will be presented in Barcelona , Spain in UEGW (United european gastroenterology week) October 23 to October 27th 2010 UEGW Barcelona 2010 October 23 - 27, 2010 Barcelona/Spain Dear Prof GILL,  Thank you for having submitted an abstract for "UEGW 2010" to be held in Barcelona this October.  Congratulations! Your abstract […]

Hepatitis C is a growing menace in our country. Early detection of the disease and timely intervention in terms of treatment is still the burning issue. Standard of care for treatment of chronic hepatitis C is weekly injection of Peg –interferon and Ribavirin.Its efficacy is 80% in our population. Unfortunately we are facing new challenges […]

Consensus interferon treatment for Pegylated interferon relapsers Hepatitis C patients rated the best study by Pakistan Society of Gastroenterology Annual conference in Bhurbun Muree May 30th 2010. OUTCOMES OF CONSESUS INTERFERON AND RIBAVIRIN THERAPY FOR CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS WHO RELAPSED WITH PREVIOUS PEGYLATED INTERFERON AND RIBAVIRIN THERAPY. Authors: Uzma Adeeb ,Fatima Khattak […]

Consensus interferon treatment for Pegylated interferon relapsers Hepatitis C patients rated the best study by Pakistan Society of Gastroenterology Annual conference in Bhurbun Muree May 30th 2010.

Chronic Hepatitis C treatment is a rapidly changing arena. There are rapidly changing guidelines about the type of interferon use and duration of treatment. We are able to understand the disease process better after 20 years of research to improve the diagnostic tools and treatment type and duration. There are new tools and parameters, both […]

Dr. Gill is invited to the International Liver CongressTM 2010 by EASL, taking place in Vienna, Austria, April 14 to 18, 2010. On behalf of the Scientific Programme Committee, we are very pleased to inform you that your abstract A-248-0025-00251 entitled: "RAPID VIROLOGICAL RESPONSE IS A PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEP C […]

Dr. Gill is invited to the 20th Conference of the APASL, to be held at the China National Convention Center, 25 to 28 March 2010, Beijing, China. Thank you very much for submitting abstract(s) to the 20th Conference of the APASL. On behalf of the Scientific Committee, we are pleased to inform you that your […]

New treatment for hep c non responders and relapsers